At 250-500 mg, single oral dose:

• Onset is subtle. Most users do not feel acute single-dose effects the way they do with alpha-GPC at 600 mg or modafinil at 100 mg. Onset is gradual, peaks ~3-4 hr post-dose, and the effect is more "background availability of cognitive resources" than "felt activation."
• Some users report mild mental clarity, easier task initiation, and slightly faster word recall ~2-4 hr post-dose. ~30-50% of users report no acute felt effect on first dose — this is normal and not a sign the supplement isn't working.

At 500 mg/day chronic (the canonical stack dose):

• The effect is chronic and subtle, not acute and dramatic. Most users describe it as showing up over 2-4 weeks of daily dosing — a baseline shift toward easier sustained attention, cleaner working memory, better follow-through on long tasks, less "where was I going with this" mid-sentence.
• Most reliably felt on stopping — users who cycle off after 4+ weeks of daily 500 mg often report a noticeable drop in cognitive baseline, similar to dropping out of regular exercise.
• No felt stimulation, no jitter, no peripheral effects. This is a "substrate" feel, not an "activator" feel — closer to magnesium or fish oil than to caffeine or modafinil.

At 1000-2000 mg/day (clinical trial range):

• More noticeable subjective effect; some users at 2000 mg report mild euphoria, increased motivation, or "slightly upbeat" mood — likely the dopamine D2 upregulation mechanism. A minority report mild restlessness or insomnia at higher doses, particularly evening dosing.
• GI tolerance generally good but some users report mild nausea or loose stool above 1500 mg/day, especially without food.

Variability:

• Diet interaction: the user's diet (chicken/rice/avocado, fruit, gluten-free home cooking) is moderate-choline at best — not egg-rich or liver-rich. This is a profile that should respond to supplementation. Heavy-egg / heavy-organ-meat eaters often feel less from citicoline because they're already choline-replete.
• CHAT/CHRM/CHRNA polymorphisms modulate downstream acetylcholine signaling efficiency.
• APOE ε4 carriers may benefit more from cholinergic support (cholinergic deficit appears earlier in ε4 carriers; relevant for users in this archetype post-23andMe ~June 5-15).

• Acute single-dose tolerance: none observed. Citicoline is a substrate, not a receptor agonist; the underlying ChAT and Kennedy pathways do not downregulate with chronic exposure.
• Chronic tolerance: minimal-to-none. Multi-month and multi-year clinical trials in vascular cognitive impairment and stroke recovery show sustained efficacy at 1000-2000 mg/day over 6-24 months without escalation. This is consistent with the substrate-mechanism profile.
• Recommended cycle for users in this archetype: continuous daily use, no cycling needed. This is one of the few supplements where chronic continuous dosing is unambiguously the right pattern.
• Reset protocol: none required. If discontinuing for any reason, no withdrawal effect; effect simply tapers as choline/cytidine substrate pool returns to dietary baseline over 1-2 weeks.

Synergistic with

• alcar: ✅ Already in the canonical stack plan (ALCAR 500 mg AM). ALCAR provides acetyl groups for ChAT; citicoline provides choline + cytidine. Substrate pair → maximal acetylcholine production + Kennedy-pathway membrane support. Standard "ACD" stack (ALCAR + CDP-choline + DHA) — users in this archetype often already run all three components in V4/V5.
• DHA / fish oil: ✅ Already in V4 (Carlson Super DHA Gems, 2 g DHA/day). The Wurtman synaptogenesis triad — uridine (from citicoline) + choline + DHA — is the molecular substrate of synaptic-density increase. This is the strongest mechanistically-grounded stack in the canonical stack.
• phosphatidylserine (PS): ✅ Already in V4 (Swanson PS, 200 mg/day). PS is another phospholipid head-group; citicoline-derived phosphatidylcholine + supplemental PS together support membrane phospholipid diversity. Standard cognitive-aging stack.
• n-acetyl-cysteine (NAC): ✅ Already in V4 (Swanson NAC, 1200 mg/day). Mechanistically orthogonal — NAC is glutathione precursor; citicoline is cholinergic substrate. Stack-safe; both used in glaucoma and cognitive-aging protocols.
• magnesium glycinate / magnesium L-threonate: ✅ Already in V4 (Doctor's Best Mg Glycinate 400 mg + Source Naturals Magtein 3 caps). NMDA modulation + cholinergic support are complementary. Stack-safe.
• caffeine + L-theanine: ✅ Standard nootropic combo. Citicoline provides cholinergic substrate; caffeine antagonizes adenosine; theanine smooths the activation. All four together is the canonical "study stack."
• modafinil: ✅ Modafinil increases cortical activation and acetylcholine demand; citicoline supplies the substrate. Anecdotally smooths modafinil cognitive ceiling on hard workdays. Stack-safe; no PK interaction. Relevant for the canonical stack modafinil onboarding.
• bromantane: ✅ Bromantane upregulates tyrosine hydroxylase + dopamine synthesis; citicoline's cholinergic complement balances the catecholaminergic tilt. V5 stack alignment.
• n-acetyl-semax-amidate (NA-Semax-amidate) / semax: ✅ Russian peptide neurotrophic agent (BDNF/NGF upregulation) is mechanism-orthogonal. Many Russian-peptide users pair with citicoline as standard cholinergic baseline. Stack-safe.
• selank: ✅ Anxiolytic peptide, mechanism-orthogonal. Stack-safe.
• Racetams (piracetam, aniracetam, oxiracetam, pramiracetam, phenylpiracetam): ✅ Mandatory pairing. Racetams increase cholinergic demand (the precise mechanism is debated but the empirical pattern is consistent across 50+ years of clinical and underground use). Without choline supplementation, racetams produce tension headaches in 1-3 days for ~50% of users. Citicoline 250-500 mg/day is the standard solution. For the user: if he ever cycles racetams, citicoline at 500 mg/day continues unchanged — already covered.
• huperzine A (intermittent): ⚠️ Generally compatible at PRN doses (50-100 mcg) with citicoline 500 mg. Cholinergic excess unlikely at these doses. At chronic high-dose huperzine (>200 mcg/day daily) + citicoline 500 mg, watch for cholinergic side effects.
• L-tyrosine: ✅ Catecholamine substrate; citicoline is cholinergic substrate. Both PRN under cognitive load. Stack-safe.
• Rhodiola, ashwagandha: ✅ Adaptogens are mechanism-orthogonal.
• Curcumin phytosome: ✅ Anti-inflammatory; mechanism-orthogonal. Already in V4.

Avoid stacking with (or use with caution)

• Alpha-GPC at chronic full daily dose simultaneously: ⚠️ Don't double-dose choline. Both elevate plasma choline; choline transport saturates around the 500-1000 mg-choline-equivalent range. Stacking citicoline 500 mg + alpha-GPC 600 mg daily isn't dangerous but is redundant — diminishing returns above saturation. The clean play for users in this archetype: citicoline 500 mg/day chronic baseline + alpha-GPC 300-600 mg PRN on heavy-cognitive-task days only (2-4×/week). Not double-daily.
• Multiple chronic choline donors (citicoline + alpha-GPC + lecithin + choline bitartrate + CDP-choline): ❌ Stacking past saturation produces dysphoria/depression in some users (the "too much choline" pattern). Pick one primary chronic donor.
• Donepezil, galantamine, rivastigmine (Rx AChE inhibitors): ⚠️ Theoretical cholinergic excess; relevant in elderly Alzheimer's patients, not for users in this archetype.
• High-dose nicotine + citicoline + alpha-GPC + huperzine simultaneously: ⚠️ Cholinergic stacking; mild concern, not absolute contraindication.

Neutral / safe co-administration

• All current Canonical stack items: NAC, magnesium glycinate, magnesium L-threonate, PS, curcumin, rhodiola, theanine, glycine (or L-tryptophan), D3+K2, beta-alanine, vitamin C, fish oil, creatine.
• All planned V5 additions: modafinil, bromantane, Adamax/Semax, ALCAR, apigenin, taurine, astaxanthin, L-tryptophan, selegiline, Cerebrolysin (cycled).
• All PRN tools (alpha-GPC at PRN dose, sulbutiamine, pramiracetam, propranolol, L-tyrosine, Selank).

• CYP enzymes: Citicoline does not meaningfully induce or inhibit CYP enzymes. Pharmacokinetic interactions essentially nil.
• Anticoagulants / antiplatelets (warfarin, aspirin, clopidogrel): No documented clinically significant interaction. Theoretical mild platelet-modulating effect at high doses (>2000 mg/day), but no clinical signal.
• L-DOPA / Parkinson's medications: Citicoline is sometimes used adjunctively in Parkinson's; some evidence of L-DOPA dose-sparing effect. Not adverse.
• Anticholinergic drugs (oxybutynin, TCAs, first-gen antihistamines): Citicoline may partially counter their effects (mutual antagonism). Not dangerous, just may reduce anticholinergic efficacy.
• Hormonal contraceptives: No interaction.
• Modafinil, armodafinil: No CYP interaction. Stack-safe.
• SSRIs / SNRIs: No interaction. Stack-safe.

Limited direct PGx data for citicoline specifically. Relevant indirect variants:

• APOE ε4: APOE ε4 carriers show earlier cholinergic deficit; may benefit more from chronic cholinergic substrate. Relevant for users in this archetype post-23andMe (~June 5-15, 2026) — if he is APOE ε4+, citicoline moves from STRONG-CANDIDATE to "mandatory" status for chronic brain-preservation.
• CHAT (choline acetyltransferase): polymorphisms may modulate downstream acetylcholine synthesis efficiency. Limited clinical translation data.
• CHRM1, CHRM2, CHRNA4, CHRNA7 (cholinergic receptors): theoretical modulators of cognitive response. Limited data.
• CTL1 / SLC44A1 (choline BBB transporter): rare variants affect choline brain uptake.
• FMO3: governs TMAO production from gut-derived TMA. the user's 23andMe will reveal common variants (rs2266782/E158K, rs2266780/V257M, rs1736557/E308G). For citicoline at 500 mg/day, the TMAO load is modest enough that FMO3 status is unlikely to change the verdict — but worth noting alongside ALCAR and alpha-GPC FMO3 implications.
• MTHFR / methylation panel: relevant indirectly because phosphatidylcholine biosynthesis intersects with one-carbon metabolism. MTHFR C677T homozygotes may benefit slightly more from citicoline's bypass of de-novo PC synthesis (which requires methylation via PEMT pathway).

Action for users in this archetype: When 23andMe results land (~June 5-15, 2026), check APOE status primarily. If APOE ε4+, citicoline locks in as permanent core stack item. FMO3 is secondary but worth noting.

Recommendation for users in this archetype: Continue Healthy Origins Cognizin Citicoline 250 mg × 150 caps via iHerb, ~$45/bottle = 2.5 months supply at 500 mg/day = ~$18/month. Already in V4 supply chain; trial-aligned form; no reason to switch.

Cost-optimization option: If the user ever wants to cut cost, Nutricost generic CDP-choline at ~$7-15/month is pharmacologically equivalent (post-gut-hydrolysis the molecule is the same). The Cognizin premium buys trial-aligned manufacturing rather than measurable PK advantage. Not a meaningful budget priority at his current spend.

Total cost (the user, current V4): ~$18/month for 500 mg Cognizin daily. Among the best per-dollar interventions in the canonical stack.

Baseline (before starting; not all needed for users in this archetype since already in use)

• Plasma choline + plasma uridine — niche assays; not standard. Skip.
• Lipid panel (total chol, LDL, HDL, ApoB) — baseline cardiovascular picture. Already in the user's June 2026 panel.
• hs-CRP — baseline inflammation. June 2026.
• Homocysteine — methylation status; relevant to choline metabolism (PEMT pathway). June 2026.
• CBC, CMP — general baseline. June 2026.

During use

• Subjective tracking: sustained attention, working memory, word-finding, task initiation — track over 4-8 weeks. Citicoline's effect is chronic and subtle, not acute.
• Standard labs at 6-12 months — lipid panel, hs-CRP, CMP. No specific citicoline-induced drift expected.

Post-cycle (if ever discontinued)

• Subjective baseline shift — most reliable sign of effect is what changes when stopping. Useful diagnostic if the user ever wants to confirm benefit empirically.